Lead sponsor
FORUM Pharmaceuticals Inc
8 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
8
Trials led
0
Ongoing
1,765
Total enrollment
228
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
1
Phase 2
4
Phase 3
3
Trials by status
Completed
3
Terminated
3
Withdrawn
1
Unknown
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's DiseaseAlzheimer's diseasePh 3Terminated474
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed409
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's DiseaseAlzheimer's diseasePh 3Terminated403
Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025Study partner/caregiver requiredPh 3Terminated348
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's DiseaseMCI due to ADPh 2Completed52
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's DiseaseAlzheimer's diseasePh 1Completed49
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin MutationGRN mutation requiredPh 2Unknown30
Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving MemantineAlzheimer's diseasePh 2Withdrawnnot disclosed